Hematology-Oncology – Page 5

Bridging Perspectives: Patient and Clinician Views on Postpartum Venous Thromboembolism Risk and Thromboprophylaxis Use

By MedXY 08/21/2026

This qualitative study explores patient and obstetric clinician perspectives on postpartum venous thromboembolism (VTE) risk communication and pharmacologic thromboprophylaxis, highlighting education gaps and the need for individualized risk assessment to optimize care.

Gastroenterology Hematology-Oncology news

Targeting NEK7-Mediated EGFR Phosphorylation to Overcome Lenvatinib Resistance in Hepatocellular Carcinoma

By MedXY 08/21/2026

NEK7 promotes acquired lenvatinib resistance in hepatocellular carcinoma by phosphorylating EGFR at serine 1070, activating key signaling pathways. Blocking this interaction offers a promising therapeutic avenue to counteract resistance.

Cardiology Hematology-Oncology news

Metrnl: A Novel Inhibitor of Platelet Activation Targeting CD36 to Mitigate Thrombosis and Acute Myocardial Injury

By MedXY 08/21/2026

Metrnl reduces platelet activation and thrombus formation by promoting CD36 degradation, offering a promising therapeutic strategy for thrombotic diseases including acute myocardial infarction without increasing bleeding risk.

Diabetes & Endocrinology Hematology-Oncology news

Dulaglutide Versus Insulin in Adolescents With Thalassaemia-Induced Diabetes: Improving Glycaemic Control and Metabolic Health in a High-Risk Population

By MedXY 08/21/2026

The DIADEMA trial demonstrates dulaglutide's superiority over insulin in improving glycaemic variability, pancreatic function, and iron overload, without safety concerns, in adolescents with thalassaemia-induced diabetes.

Hematology-Oncology news Oncology

Delineating the Roles of Federal and Industry Sponsorship in US Cancer Clinical Trials

By MedXY 08/21/2026

This study compares US federally sponsored and industry-sponsored cancer clinical trials, highlighting differences in trial focus, populations, and interventions, and underscoring their complementary roles in advancing oncology research.

Hematology-Oncology news OB/GYN & Women’s Health

Ovarian Tissue Cryopreservation After Hematopoietic Stem Cell Transplantation: A Viable Fertility Preservation Strategy in Selected Females

By MedXY 08/20/2026

This study evaluates ovarian tissue cryopreservation (OTC) feasibility in girls and young women post-hematopoietic stem cell transplantation (HSCT), demonstrating OTC as a potential fertility salvage option despite reduced ovarian reserve after HSCT.

Clinical Updates Hematology-Oncology news

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap

By MedXY 08/20/2026

This review explores the Global Lymphoma Registry Alliance’s roadmap for leveraging multinational real-world data collaborations to address lymphoma’s heterogeneity, optimize treatment strategies, and improve patient outcomes worldwide through data harmonization, multi-stakeholder collaboration, and innovative registry integration.

Hematology-Oncology news

Pre-Diagnostic Low-Normal Immunoglobulin Levels Identify Early Clonal B-cell Dysregulation and CLL Susceptibility: Insights from a Large Retrospective Cohort

By MedXY 08/20/2026

Low-normal immunoglobulin levels, particularly IgA, measured up to a decade before diagnosis, are predictive of chronic lymphocytic leukemia risk through dual mechanisms involving monoclonal B-cell lymphocytosis and constitutional susceptibility.

$Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease$

Hematology-Oncology news Oncology

Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease

By MedXY 08/20/2026

Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.

Hematology-Oncology news OB/GYN & Women’s Health

Preventing Maternal Deaths from Venous Thromboembolism: Insights from a 12-Year Nationwide French Analysis

By MedXY 08/19/2026

A nationwide French study reveals that nearly half of maternal deaths due to venous thromboembolism are preventable, emphasizing the importance of ongoing risk assessment and appropriate thromboprophylaxis during pregnancy and postpartum.

Hematology-Oncology news Oncology

Relapse and Survival Benchmarks in Non-Transplanted AML Patients Achieving First Complete Remission

By MedXY 08/17/2026

A retrospective study delineates relapse risks and survival outcomes in adult acute myeloid leukemia patients who achieve first complete remission without undergoing allogeneic stem cell transplantation, highlighting venetoclax’s role in reducing relapse.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Decoding Bone Marrow Architecture: A New Biomarker for Disease Activity and Treatment Response in Myelodysplastic Neoplasms

By MedXY 08/17/2026

Spatial remodeling of bone marrow in myelodysplastic neoplasms (MDS) reveals distinctive tissue-state signatures that better capture disease activity and predict therapeutic response beyond traditional blast counts.

$Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma$

Hematology-Oncology news Oncology

Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma

By MedXY 08/17/2026

This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating alloSCT for high-risk cases.

Hematology-Oncology news

Unraveling the Blockade: How Mutant IDH1 Impairs Neutrophil Differentiation in Preleukemic Hematopoiesis

By MedXY 08/17/2026

Mutant IDH1 in acute myeloid leukemia causes a reversible block in neutrophil differentiation by repressing myeloid progenitor transcriptional programs, highlighting a preleukemic defect with therapeutic implications.

Hematology-Oncology news Oncology

Chemotherapy-Free Frontline Therapy in Indolent B-Cell Non-Hodgkin Lymphoma: Insights from Mosunetuzumab and Response-Adapted Polatuzumab Vedotin with Obinutuzumab

By MedXY 08/17/2026

A novel chemotherapy-free regimen combining mosunetuzumab with response-adapted polatuzumab vedotin and obinutuzumab shows high complete response rates and durable progression-free survival in untreated indolent B-cell NHL with favorable safety.

Dermatology Hematology-Oncology news

Risk Stratification Models in Blood or Marrow Transplant Recipients for Predicting Cutaneous Malignant Neoplasms

By MedXY 08/16/2026

Blood or marrow transplant recipients face an increased risk of skin cancers. This study develops validated risk models to identify high-risk patients for basal cell carcinoma, squamous cell carcinoma, and melanoma to optimize surveillance strategies.

Hematology-Oncology news Rheumatology

Low-dose Blinatumomab Therapy in Multidrug-Resistant Rheumatoid Arthritis: A Case Series Analysis

By MedXY 08/16/2026

A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffective DMARDs.

Hematology-Oncology news Pathology & Lab Medicine

ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to know

By MedXY 08/15/2026

The ELN‑DAVID 2026 technical note establishes standards for NGS-based detection of FLT3‑ITD measurable residual disease (MRD) in AML, with lab validation, reporting, timing, and clinical-use recommendations to make FLT3‑ITD MRD testing actionable in routine care.

Hematology-Oncology news

Real-World Incidence, Risk Factors, and Biomarker Validation for SOS/VOD After Allogeneic HSCT in Adults: Insights from the Spanish GETH-TC Registry

By MedXY 08/12/2026

A comprehensive retrospective analysis of 793 adult allo-HSCT cases identifies key clinical risk factors and validates the EASIX score as a predictive biomarker for SOS/VOD, highlighting the syndrome's significant impact on non-relapse mortality.

Clinical Updates Hematology-Oncology news

Lenalidomide and Oral Azacitidine Combined with Radiotherapy in Plasmacytoma: A Pilot Trial and Perspectives

By MedXY 08/12/2026

This review synthesizes evidence on combining lenalidomide and oral azacitidine with radiotherapy for plasmacytoma, highlighting safety, preliminary efficacy, and translational rationale in newly diagnosed and relapsed patients.